3160 PORTER DR., PALO ALTO, CA
Submits NDA to FDA for Encaleret for Individuals Living with ADH1
News
Reports First Quarter 2026 Financial Results and Corporate Updates
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
Other Events
Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Preliminary Unaudited Q4 and Full Year 2025 Results
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Confidential Treatment Order